Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Financial Results:
Neuland Laboratories Ltd reported Revenues for Q4FY24 of ₹385.00 Crores down from ₹407.00 Crore year on year, a fall of 5.41%.
Total Expenses for Q4FY24 of ₹298.00 Crores down from ₹304.00 Crores year on year, a fall of 1.97%.
Consolidated Net Profit of ₹68.00 Crores down 20.0% from ₹85.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹52.66, down 20.08% from ₹65.89 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.